| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | A-443654 | GDSC1000 | pan-cancer | AAC | -0.0087 | 0.9 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.9 |
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | -0.0087 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |